TRVI logo

TRVI
Trevi Therapeutics Inc

1,796
Mkt Cap
$1.69B
Volume
973,542.00
52W High
$14.39
52W Low
$5.38
PE Ratio
-41.12
TRVI Fundamentals
Price
$13.19
Prev Close
$13.30
Open
$13.43
50D MA
$11.50
Beta
0.62
Avg. Volume
1.38M
EPS (Annual)
-$0.3173
P/B
9.24
Rev/Employee
$0.00
$1,499.53
Loading...
Loading...
News
all
press releases
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2% - Here's What Happened
Trevi Therapeutics (NASDAQ:TRVI) Trading 7.2% Higher - Time to Buy...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One...
MarketBeat·15d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4% - What's Next?
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 9.4% - What's Next...
MarketBeat·17d ago
News Placeholder
Research Analysts Issue Forecasts for TRVI FY2026 Earnings
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for Trevi Therapeutics in a research note issued on Wednesday, March 18th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.54) per sha...
MarketBeat·23d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading
JonesTrading reduced their target price on shares of Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday...
MarketBeat·23d ago
News Placeholder
What is HC Wainwright's Forecast for TRVI Q1 Earnings?
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Trevi Therapeutics in a note issued to investors on Wednesday, March 18th. HC Wainwright analyst B. Folkes expects that the company will earn ($0.08) per share...
MarketBeat·24d ago
News Placeholder
Trevi Therapeutics Q4 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data...
MarketBeat·24d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley
Morgan Stanley reduced their price target on Trevi Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Wednesday...
MarketBeat·24d ago
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Earnings Beat...
MarketBeat·25d ago
News Placeholder
Trevi Therapeutics (TRVI) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·25d ago
<
1
2
...
>

Latest TRVI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.